Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-Vcan siRNA nanoparticles
- Development stage
- Preclinical
- Lead developer
- Champalimaud Foundation
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Intraperitoneal, Intratumoral
01
Overview
anti-Vcan siRNA nanoparticles are a preclinical therapeutic candidate designed to target the bone marrow microenvironment in multiple myeloma. The drug consists of small interfering RNA (siRNA) molecules encapsulated in nanoparticles, specifically targeting the expression of Versican (Vcan), an extracellular matrix proteoglycan. In preclinical models, Vcan is highly expressed by pro-tumoral myeloma-associated macrophages (MAMs). By silencing Vcan, these nanoparticles modulate the immune microenvironment, leading to a reduction in the expression of immune checkpoint molecules such as PD-L1 on macrophages and PD-1 on CD4+ and CD8+ T cells, thereby potentially overcoming immunosuppression and enhancing anti-tumor immunity.
- Other names
- anti-Vcan molecules
02
Targets
VCAN (Versican / VCAN)
Beyond the preview
Go deeper on anti-Vcan siRNA nanoparticles.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-Vcan siRNA nanoparticles.